Literature DB >> 1963072

Leukotrienes in the sputum and urine of cystic fibrosis children.

A P Sampson1, D A Spencer, C P Green, P J Piper, J F Price.   

Abstract

1. Leukotrienes (LTs) are potent pro-inflammatory mediators with actions relevant to the pathophysiology of cystic fibrosis (CF), including increased mucus production, bronchoconstriction, leucocyte chemotaxis, and increased vascular permeability. We have therefore investigated the potential role of LTs in children with CF. Leukotriene E4 levels were assessed in the urine of 30 normal (N) children (aged 1.3-12.7 years) and 30 CF children (1.6-14.3 years). Sputum from 13 of the CF children was analysed from LTB4, LTC4, LTD4, and LTE4. LTs were separated by reversed-phase h.p.l.c. and quantitated by radioimmunoassay. 2. Urinary LTE4 levels were log normally distributed, with geometric mean values (95% confidence intervals) of N: 88.4 (71.3-111) pmol mmol-1 creatinine (n = 30), and CF: 112 (70.6-177) pmol mmol-1 creatinine (n = 30; P greater than 0.05). Of the CF subjects, 33% had urinary LTE4 levels above 200 pmol mmol-1 creatinine, compared with 3.3% of the N children. 3. In sputum, mean (+/- s.e. mean) LT concentrations were (pmol g-1), LTB4: 44.3 +/- 10.8, LTC4: 4.9 +/- 1.3, LTD4: 1.8 +/- 0.9, and LTE4: 67.7 +/- 18.9 (n = 13). 4. Urinary LTE4 levels correlated significantly with sputum LTE4 levels (r = 0.673, P = 0.012), and with sputum levels of total cysteinyl-LTs (r = 0.660, P = 0.014). 5. In conclusion, total cysteinyl-LT content in sputum is 10-fold higher than previously reported, consisting primarily (91%) of LTE4. The high levels of LTE4 and LTB4 in sputum suggest involvement of LTs in the pathophysiology of CF. Urinary LTE4 levels may prove useful as a marker for cysteinyl-LT production in sputum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1963072      PMCID: PMC1368307          DOI: 10.1111/j.1365-2125.1990.tb05452.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  J T Zakrzewski; N C Barnes; J F Costello; P J Piper
Journal:  Am Rev Respir Dis       Date:  1987-09

2.  Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect.

Authors:  J Carlstedt-Duke; M Brönnegård; B Strandvik
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Stability of leukotrienes C4 and D4 in human urine.

Authors:  G Beyer; C O Meese; U Klotz
Journal:  Prostaglandins Leukot Med       Date:  1987-10

4.  The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals.

Authors:  J Verhagen; E H Bel; G M Kijne; P J Sterk; P L Bruynzeel; G A Veldink; J F Vliegenthart
Journal:  Biochem Biophys Res Commun       Date:  1987-10-29       Impact factor: 3.575

5.  Identification of leukotrienes D and B in sputum from cystic fibrosis patients.

Authors:  O Cromwell; M J Walport; H R Morris; G W Taylor; M E Hodson; J Batten; A B Kay
Journal:  Lancet       Date:  1981-07-25       Impact factor: 79.321

6.  Metabolism and analysis of endogenous cysteinyl leukotrienes.

Authors:  D Keppler; M Huber; W Hagmann; H A Ball; A Guhlmann; S Kästner
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

7.  Stimulation of human leukocyte degranulation by leukotriene B4 and its omega-oxidized metabolites.

Authors:  S J Feinmark; J A Lindgren; H E Claesson; C Malmsten; B Samuelsson
Journal:  FEBS Lett       Date:  1981-12-21       Impact factor: 4.124

8.  Critical considerations in the development of an assay for sulfidopeptide leukotrienes in plasma.

Authors:  D J Heavey; R J Soberman; R A Lewis; B Spur; K F Austen
Journal:  Prostaglandins       Date:  1987-05

9.  Chemotaxis of human neutrophils and eosinophils towards leukotriene B4 and its 20-w-oxidation products in vitro.

Authors:  B M Czarnetzki; T Rosenbach
Journal:  Prostaglandins       Date:  1986-05

10.  Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis.

Authors:  H Gilljam; B Strandvik; A Ellin; L G Wiman
Journal:  Scand J Clin Lab Invest       Date:  1986-10       Impact factor: 1.713

View more
  18 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis.

Authors:  R H Lawrence; T C Sorrelli
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

3.  Corticosteroid treatment in cystic fibrosis.

Authors:  J F Price; P Greally
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 4.  Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Authors:  Sabina Schmitt-Grohé; Stefan Zielen
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  LTB4 is present in exudative pleural effusions and contributes actively to neutrophil recruitment in the inflamed pleural space.

Authors:  E Pace; M Profita; M Melis; A Bonanno; A Paternò; C H Mody; M Spatafora; M Ferraro; L Siena; A M Vignola; G Bonsignore; M Gjomarkaj
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

6.  Effects of mucoid and non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients on inflammatory mediator release from human polymorphonuclear granulocytes and rat mast cells.

Authors:  P Friedl; B König; W König
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

7.  Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis.

Authors:  R H Lawrence; T C Sorrell
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

8.  Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.

Authors:  P Greally; M J Hussein; A J Cook; A P Sampson; P J Piper; J F Price
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

9.  Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis.

Authors:  J Roca-Ferrer; L Pujols; S Gartner; A Moreno; F Pumarola; J Mullol; N Cobos; C Picado
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

Review 10.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.